BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:"My Genome and We - The Dawn of Participatory Medicine"
DTSTART:20111221T160000
DTSTAMP:20260916T050606Z
UID:07efaebb9324a2d8800772bf623908e7680c9c30fb72f54239fdfeaf
CATEGORIES:Conferences - Seminars
DESCRIPTION:Prof. Ernst Hafen - Institute of Molecular Systems Biology - E
 THZ\nTen years ago sequencing of the human genome costed 3 billion dollars
 . Owing to rapid technological progress - almost exclusively in the United
  States -  DNA sequencing costs are dropping precipitously. The current pr
 ice of a full genome sequence is already approaching the $ 1'000 mark. In 
 less than two years the complete genome sequence of individuals will be av
 ailable for Fr. 100.00 thus laying the basis for P4 (Predictive\, Preventi
 ve\, Personalized\, Participatory) medicine. Already today whole genome se
 quence data are changing how diseases\, particularly cancer\, are treated.
  In some cases rare mutations have been identified that led to successful 
 treatment of terminally ill patients. Companies like 23andme.com   offer g
 enome analysis directly to consumers and provide information on the statis
 tical susceptibility to more than a hundred diseases and traits. On the ot
 her hand\, the ability for people do donate their genome information\, med
 ical and phenotypic information in anonymized form to medical research is 
 transforming how research is done and offers the chance to make research a
  participatory effort. The ubiquitous availability of personal genome sequ
 ences\, however\, also poses challenges to society. What do these sequence
 s mean to the individual\, how are the sequences kept beyond the research 
 of employers and insurance companies and finally what does an individual d
 o probabilities to get a disease. How can the right "not to know" be infor
 ced. Given the rapid technological progress\, the potential of engaging th
 e public into health research for the benefit of society and the legal and
  ethical challenges associated with this technology it is important to sta
 rt  the public discourse on this topic now. In this talk I will briefly re
 view the current state of genome wide analysis\, the technological progres
 s and my own experience with the analysis of my genome and that of my fami
 ly. I will discuss how Switzerland could take a leading position in moving
  P4 health forward. 
LOCATION:SV1717A
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR